Oncology

A combination of sitting for longer periods a day and a lack of physical activity resulted in a higher risk of death than those who partook in physical activity.

Safety findings from the phase 1 ASPEN-01 trial support the use of evorpacept with or without pembrolizumab or trastuzumab for patients with advanced solid tumors.

A cohort study found that immune-mediated diseases were associated with a higher increased risk of total cancer, and organ-specific immune-mediated diseases were more strongly associated with local cancers than extra-local cancers.

In recognition of World Cancer Day, Daniel Vorobiof, MD, touched on the use of Belong.life, a patient-centric social and professional network, in collecting real-world data and providing patients with additional resources, and highlighted several real-world data studies that were conducted with the application’s data.

For World Cancer Day, CancerNetwork® reviews key highlights from the Cancer Facts & Figures 2022 report from the American Cancer Society, with updates in cancer incidence, mortality, and survival across patient subgroups.

Fosnetupitant demonstrated non-inferiority and a favorable safety profile vs fosaprepitant for chemotherapy-induced nausea and vomiting.

In radiation oncology and medical oncology, representation of female faculty has increased from 1970 to 2019, and representation of individuals from historically underrepresented racial and ethnic groups in medicine remains low.

Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.

Suicide risk increased among patients who had a lower-income and lived in rural counties following a cancer diagnosis.

The proposed Most Favored Nation pricing model, which would have had a significant negative impact on cancer care in the United States, has been withdrawn by the Centers for Medicare & Medicaid Services.

This episode features Don Dizon, MD, discussing how LGBTQ+ patients with cancer navigate the world of cancer care, and the critical steps needed to improve their experiences.

An interim analysis demonstrated positive efficacy and safety in patients with metastatic solid tumors who were treated with etigilimab plus nivolumab.

Black and Hispanic patients continue to be notably underrepresented in clinical cancer research, although research noted that participation is on the rise.

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.

Investigators identified an association between the early expansion of Medicaid and a reduction in cancer-related mortality.

Aparna Parikh, MD, MS, discusses how her early experiences with physical fitness shaped her current relationship with exercise.

The Build Back Better Act could increase drug and related expenses could eventually lead to the closure of independent oncology practices.

Findings from a Nationally Representative study indicated that multispecialty, academically affiliated, urban cancer institutions had more access to genetic testing.

The FDA approved nab-sirolimus as the first drug specifically indicated for the treatment of patients with malignant perivascular epithelioid cell tumors.

Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

ASTCT recently published an article in their journal Nucleus detailing the use of killer immunoglobulin-like receptor–ligand mismatch and its impact on graft versus host disease.

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

The Partnership Director at GRYT Health opened up about their collaboration with Bristol Myers Squibb to address disparities in clinical trials.

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Use of a multidisciplinary geriatric assessment-driven intervention resulted in a reduction in grade 3 or higher chemotherapy-related toxic events.

ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

ONCOLOGY® co-editor-in-chief Julie M. Vose, MD, MBA, recaps the 2021 Leadership, Empowerment, and Development Conference: Enriching and Supporting Women in Hematology and Oncology.

Eric D. Whitman, MD, discusses the clinical trial program at Atlantic Health System, a large nonprofit health care network in New Jersey, and how partnering with the Translational Genomics Research Institute will help to bring better care to patients with cancer.